Baker Bros. Makes $158M Kymera Bet in Major Biotech Move
Baker Bros. Makes a Massive Kymera Therapeutics Buy — Here’s the Strategic Read A Major Institutional Bet on a Rising Biotech Baker Bros. Advisors — one of the most influential biotech investment firms in the United States — has taken a large new position in Kymera Therapeutics (NASDAQ: KYMR), according to aggregated institutional-activity data from…









